PubRank

Brian F Gage

Author PubWeight™ 108.53‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005 8.77
2 Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care 2005 7.73
3 A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 2013 7.09
4 Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol 2010 5.07
5 CYP4F2 genetic variant alters required warfarin dose. Blood 2008 4.23
6 Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 2009 3.44
7 Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 2010 2.93
8 Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation 2009 2.93
9 Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 2011 2.80
10 Influence of nitrous oxide anesthesia, B-vitamins, and MTHFR gene polymorphisms on perioperative cardiac events: the vitamins in nitrous oxide (VINO) randomized trial. Anesthesiology 2013 2.39
11 Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA 2005 2.38
12 High-sensitivity cardiac troponin T in prediction and diagnosis of myocardial infarction and long-term mortality after noncardiac surgery. Am Heart J 2013 2.30
13 Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost 2005 2.25
14 Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood 2007 2.23
15 Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified? Stroke 2007 2.22
16 Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials 2010 1.72
17 Cost-effectiveness of outpatient cardiac monitoring to detect atrial fibrillation after ischemic stroke. Stroke 2010 1.71
18 Preference-based antithrombotic therapy in atrial fibrillation: implications for clinical decision making. Med Decis Making 2005 1.68
19 Can we rely on RE-LY? N Engl J Med 2009 1.58
20 Effects of phosphodiesterase type 5 inhibition on systemic and pulmonary hemodynamics and ventricular function in patients with severe symptomatic aortic stenosis. Circulation 2012 1.56
21 Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke 2006 1.53
22 Use of EPO in critically ill patients with acute renal failure requiring renal replacement therapy. Am J Kidney Dis 2005 1.49
23 Implantable cardioverter-defibrillator therapy improves long-term survival in patients with unexplained syncope, cardiomyopathy, and a negative electrophysiologic study. Heart Rhythm 2005 1.48
24 Genetic warfarin dosing: tables versus algorithms. J Am Coll Cardiol 2011 1.43
25 Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population. Pharmacoepidemiol Drug Saf 2010 1.43
26 Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thromb Haemost 2011 1.35
27 Cost-effectiveness of extending Medicare coverage of immunosuppressive medications to the life of a kidney transplant. Am J Transplant 2004 1.33
28 Comorbidity indices to predict mortality from Medicare data: results from the national registry of atrial fibrillation. Med Care 2005 1.31
29 Predictors of mortality in younger and older patients with heart failure and preserved or reduced left ventricular ejection fraction. Am Heart J 2003 1.19
30 Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose. Am J Clin Pathol 2008 1.17
31 Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial. Am Heart J 2013 1.12
32 Clinical Benefit of American College of Chest Physicians versus European Society of Cardiology Guidelines for Stroke Prophylaxis in Atrial Fibrillation. J Gen Intern Med 2015 1.12
33 Anemia does not predict mortality in elderly patients with heart failure. Am J Geriatr Cardiol 2007 1.11
34 An invasive strategy is associated with decreased mortality in patients 80 years and older with acute myocardial infarction. Am J Geriatr Cardiol 2007 1.03
35 Optimal initial dose adjustment of warfarin in orthopedic patients. Ann Pharmacother 2007 1.03
36 Gamma-glutamyl carboxylase and its influence on warfarin dose. Thromb Haemost 2010 1.02
37 Effect of warfarin nonadherence on control of the International Normalized Ratio. Am J Health Syst Pharm 2004 1.01
38 Reliability for grading acute rejection and airway inflammation after lung transplantation. J Heart Lung Transplant 2005 0.98
39 American Heart Association atrial fibrillation research summit: a conference report from the American Heart Association. Circulation 2011 0.97
40 The analysis of bleeding risk-prediction scores should include all major bleeds. J Am Coll Cardiol 2013 0.97
41 Cost of dabigatran for atrial fibrillation. BMJ 2011 0.94
42 Physician and nurse acceptance of technicians to screen for geriatric syndromes in the emergency department. West J Emerg Med 2011 0.94
43 The pharmacogenetics of coumarin therapy. Pharmacogenomics 2005 0.93
44 The management of anticoagulants in the periendoscopic period for patients with atrial fibrillation: a decision analysis. Am J Med 2004 0.92
45 Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy. Clin Chem 2009 0.90
46 Use of pharmacogenetics to guide warfarin therapy. Drugs Today (Barc) 2004 0.90
47 Genotype and risk of major bleeding during warfarin treatment. Pharmacogenomics 2014 0.88
48 Risk factors for bleeding in patients taking coumarins. Curr Hematol Rep 2002 0.85
49 Substitution of generic warfarin for Coumadin in an HMO setting. Ann Pharmacother 2002 0.84
50 Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases. HIV Clin Trials 2011 0.84
51 Anemia: an independent predictor of death and hospitalizations among elderly patients with atrial fibrillation. Am Heart J 2009 0.84
52 Warfarin dose reduction vs watchful waiting for mild elevations in the international normalized ratio. Chest 2003 0.83
53 Yield of surveillance bronchoscopy for acute rejection and lymphocytic bronchitis/bronchiolitis after lung transplantation. J Heart Lung Transplant 2004 0.81
54 Cost-savings analysis of using a portable coagulometer for monitoring homebound elderly patients taking warfarin. Am J Geriatr Cardiol 2003 0.81
55 Improving adherence to coronary heart disease secondary prevention medication guidelines at a community hospital. AMIA Annu Symp Proc 2006 0.80
56 Admission international normalized ratio levels, early treatment strategies, and major bleeding risk among non-ST-segment-elevation myocardial infarction patients on home warfarin therapy: insights from the National Cardiovascular Data Registry. Circulation 2012 0.78
57 Pediatric warfarin practice and pharmacogenetic testing. Thromb Res 2010 0.78
58 ACP Journal Club. Various risk stratification schemes predict ischemic stroke and bleeding in atrial fibrillation. Ann Intern Med 2012 0.77
59 Is primary care ready for pharmacogenetics? Pharmacogenomics 2006 0.76
60 A systematic analysis and comparison of warfarin initiation strategies. Pharmacogenet Genomics 2016 0.75
61 Randomized trial of warfarin nomograms. Ann Intern Med 2004 0.75
62 Improving Prediction of Postoperative Myocardial Infarction With High-Sensitivity Cardiac Troponin T and NT-proBNP. Anesth Analg 2016 0.75
63 In reply. Anesthesiology 2014 0.75
64 Simplified peak power reserve in patients with an implantable cardioverter-defibrillator and advanced heart failure. Am J Cardiol 2005 0.75
65 Construction and validation of an automated model for the early identification of patients hospitalized for heart failure. AMIA Annu Symp Proc 2005 0.75
66 Top practice-changing articles over the last two years. J Thromb Thrombolysis 2013 0.75
67 Outpatient treatment of acute venous thromboembolic disease. Clin Chest Med 2003 0.75
68 High-Sensitivity Cardiac Troponin T Improves the Diagnosis of Perioperative MI. Anesth Analg 2017 0.75
69 Perioperative reduction of the warfarin dose. Am J Med 2003 0.75